Patents by Inventor Himanshu Brahmbhatt

Himanshu Brahmbhatt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20140155343
    Abstract: A composition comprising intact killed bacterial cells that contain a therapeutic nucleic acid, a drug or a functional nucleic acid is useful for targeted delivery to mammalian cells. The targeted delivery optionally employs bispecific ligands, comprising a first arm that carries specificity for a killed bacterial cell surface structure and a second arm that carries specificity for a mammalian cell surface receptor, to target killed bacterial cells to specific mammalian cells and to cause endocytosis of the killed bacterial cells by the mammalian cells. Alternatively, the delivery method exploits the natural ability of phagocytic mammalian cells to engulf killed bacterial cells without the use of bispecific ligands.
    Type: Application
    Filed: November 22, 2013
    Publication date: June 5, 2014
    Applicant: ENGENEIC MOLECULAR DELIVERY PTY LTD
    Inventors: HIMANSHU BRAHMBHATT, JENNIFER MACDIARMID
  • Patent number: 8735566
    Abstract: Intact, bacterially-derived minicells can safely introduce therapeutically effective amounts of plasmid-free functional nucleic acid to target mammalian cells. To this end, functional nucleic acid can be packaged into intact minicells directly, without resort to expression constructs, the expression machinery of the host cell, harsh chemicals or electroporation.
    Type: Grant
    Filed: March 21, 2008
    Date of Patent: May 27, 2014
    Assignee: Engeneic Molecular Delivery Pty Ltd
    Inventors: Himanshu Brahmbhatt, Jennifer MacDiarmid, Toby Hulf
  • Patent number: 8691963
    Abstract: Intact bacterially derived minicells containing functional nucleic acids or plasmids encoding functional nucleic acids can reduce, in targeted mammalian cells, drug resistance, apoptosis resistance, and neoplasticity, respectively. Methodology that employs minicells to deliver functional nucleic acids, targeting the transcripts of proteins that contribute to drug resistance or apoptosis resistance, inter alia, can be combined with chemotherapy to increase the effectiveness of the chemotherapy.
    Type: Grant
    Filed: August 25, 2005
    Date of Patent: April 8, 2014
    Assignee: Engeneic Molecular Delivery Pty. Ltd.
    Inventors: Himanshu Brahmbhatt, Jennifer MacDiarmid
  • Patent number: 8669101
    Abstract: Intact, bacterially-derived minicells can safely introduce therapeutically effective amounts of plasmid-free functional nucleic acid to target mammalian cells. To this end, functional nucleic acid can be packaged into intact minicells directly, without resort to expression constructs, the expression machinery of the host cell, harsh chemicals or electroporation.
    Type: Grant
    Filed: December 29, 2010
    Date of Patent: March 11, 2014
    Assignee: Engeneic Molecular Delivery Pty. Ltd.
    Inventors: Himanshu Brahmbhatt, Jennifer MacDiarmid, Toby Hulf
  • Patent number: 8591862
    Abstract: A composition comprising intact killed bacterial cells that contain a therapeutic nucleic acid, a drug or a functional nucleic acid is useful for targeted delivery to mammalian cells. The targeted delivery optionally employs bispecific ligands, comprising a first arm that carries specificity for a killed bacterial cell surface structure and a second arm that carries specificity for a mammalian cell surface receptor, to target killed bacterial cells to specific mammalian cells and to cause endocytosis of the killed bacterial cells by the mammalian cells. Alternatively, the delivery method exploits the natural ability of phagocytic mammalian cells to engulf killed bacterial cells without the use of bispecific ligands.
    Type: Grant
    Filed: July 15, 2011
    Date of Patent: November 26, 2013
    Assignee: Engeneic Molecular Delivery Pty Ltd
    Inventors: Himanshu Brahmbhatt, Jennifer Macdiarmid
  • Publication number: 20130261170
    Abstract: Intact, bacterially-derived minicells can safely introduce therapeutically effective amounts of plasmid-free functional nucleic acid to target mammalian cells. To this end, functional nucleic acid can be packaged into intact minicells directly, without resort to expression constructs, the expression machinery of the host cell, harsh chemicals or electroporation.
    Type: Application
    Filed: June 7, 2013
    Publication date: October 3, 2013
    Inventors: Himanshu Brahmbhatt, Jennifer Macdiarmid, Toby Hulf
  • Publication number: 20130236422
    Abstract: The present invention provides a method for purifying bacterial minicells that involves subjecting a sample containing minicells to density gradient centrifugation in a biologically compatible medium. The method optionally includes a preliminary differential centrifugation step and one or more filtration steps. The invention also provides a method for purifying bacterial minicells in which a sample containing minicells is subjected to a condition that induces parent bacterial cells to adopt a filamentous form, followed by filtration of the sample to separate minicells from parent bacterial cells. The inventive methods optionally include one or more steps to remove endotoxin from purified minicell preparations, and/or treatment of purified minicell preparations with an antibiotic. Additionally, the invention provides purified minicell preparations, prepared according to the foregoing methods, and containing fewer than about 1 contaminating parent bacterial cell per 107, 108, 109, 1010, or 1011 minicells.
    Type: Application
    Filed: April 17, 2013
    Publication date: September 12, 2013
    Applicant: EnGeneIC Molecular Delivery Pty. Ltd.
    Inventors: Himanshu Brahmbhatt, Jennifer MacDiarmid
  • Patent number: 8449877
    Abstract: The present invention provides a method for purifying bacterial minicells that involves subjecting a sample containing minicells to density gradient centrifugation in a biologically compatible medium. The method optionally includes a preliminary differential centrifugation step and one or more filtration steps. The invention also provides a method for purifying bacterial minicells in which a sample containing minicells is subjected to a condition that induces parent bacterial cells to adopt a filamentous form, followed by filtration of the sample to separate minicells from parent bacterial cells. The inventive methods optionally include one or more steps to remove endotoxin from purified minicell preparations, and/or treatment of purified minicell preparations with an antibiotic. Additionally, the invention provides purified minicell preparations, prepared according to the foregoing methods, and containing fewer than about 1 contaminating parent bacterial cell per 107, 108, 109, 1010, or 1011 minicells.
    Type: Grant
    Filed: April 4, 2011
    Date of Patent: May 28, 2013
    Assignee: Engeneic Molecular Delivery Pty. Ltd.
    Inventors: Himanshu Brahmbhatt, Jennifer MacDiarmid
  • Publication number: 20120208866
    Abstract: A composition comprising recombinant, intact minicells that contain a therapeutic nucleic acid molecule is disclosed. Methods for purifying a preparation of such minicells also are disclosed. Additionally, a genetic transformation method is disclosed, which comprises (i) making recombinant, intact minicells available that contain a plasmid comprised of a first nucleic acid segment, and (ii) bringing the minicells into contact with mammalian cells that are engulfing-competent, such that the minicells are engulfed by the mammalian cells, which thereafter produce an expression product of the first nucleic acid segment.
    Type: Application
    Filed: August 15, 2011
    Publication date: August 16, 2012
    Inventors: Himanshu Brahmbhatt, Jennifer MacDiarmid
  • Publication number: 20110275585
    Abstract: A composition comprising intact killed bacterial cells that contain a therapeutic nucleic acid, a drug or a functional nucleic acid is useful for targeted delivery to mammalian cells. The targeted delivery optionally employs bispecific ligands, comprising a first arm that carries specificity for a killed bacterial cell surface structure and a second arm that carries specificity for a mammalian cell surface receptor, to target killed bacterial cells to specific mammalian cells and to cause endocytosis of the killed bacterial cells by the mammalian cells. Alternatively, the delivery method exploits the natural ability of phagocytic mammalian cells to engulf killed bacterial cells without the use of bispecific ligands.
    Type: Application
    Filed: July 15, 2011
    Publication date: November 10, 2011
    Inventors: Himanshu BRAHMBHATT, Jennifer Macdiarmid
  • Patent number: 8003091
    Abstract: The present invention provides a method for purifying bacterial minicells that involves subjecting a sample containing minicells to density gradient centrifugation in a biologically compatible medium. The method optionally includes a preliminary differential centrifugation step and one or more filtration steps. The invention also provides a method for purifying bacterial minicells in which a sample containing minicells is subjected to a condition that induces parent bacterial cells to adopt a filamentous form, followed by filtration of the sample to separate minicells from parent bacterial cells. The inventive methods optionally include one or more steps to remove endotoxin from purified minicell preparations, and/or treatment of purified minicell preparations with an antibiotic. Additionally, the invention provides purified minicell preparations, prepared according to the foregoing methods, and containing fewer than about 1 contaminating parent bacterial cell per 107, 108, 109, 1010, or 1011 minicells.
    Type: Grant
    Filed: March 27, 2007
    Date of Patent: August 23, 2011
    Assignee: Engeneic Molecular Delivery Pty. Ltd.
    Inventors: Himanshu Brahmbhatt, Jennifer MacDiarmid
  • Publication number: 20110177185
    Abstract: The present invention provides a method for purifying bacterial minicells that involves subjecting a sample containing minicells to density gradient centrifugation in a biologically compatible medium. The method optionally includes a preliminary differential centrifugation step and one or more filtration steps. The invention also provides a method for purifying bacterial minicells in which a sample containing minicells is subjected to a condition that induces parent bacterial cells to adopt a filamentous form, followed by filtration of the sample to separate minicells from parent bacterial cells. The inventive methods optionally include one or more steps to remove endotoxin from purified minicell preparations, and/or treatment of purified minicell preparations with an antibiotic. Additionally, the invention provides purified minicell preparations, prepared according to the foregoing methods, and containing fewer than about 1 contaminating parent bacterial cell per 107, 108, 109, 1010, or 1011 minicells.
    Type: Application
    Filed: April 4, 2011
    Publication date: July 21, 2011
    Inventors: Himanshu BRAHMBHATT, Jennifer Macdiarmid
  • Publication number: 20110111041
    Abstract: Intact, bacterially-derived minicells can safely introduce therapeutically effective amounts of plasmid-free functional nucleic acid to target mammalian cells. To this end, functional nucleic acid can be packaged into intact minicells directly, without resort to expression constructs, the expression machinery of the host cell, harsh chemicals or electroporation.
    Type: Application
    Filed: December 29, 2010
    Publication date: May 12, 2011
    Inventors: Himanshu BRAHMBHATT, Jennifer MacDiarmid, Toby Hulf
  • Patent number: 7611885
    Abstract: The present invention provides a method for purifying bacterial minicells that involves subjecting a sample containing minicells to density gradient centrifugation in a biologically compatible medium. The method optionally includes a preliminary differential centrifugation step and one or more filtration steps. The invention also provides a method for purifying bacterial minicells in which a sample containing minicells is subjected to a condition that induces parent bacterial cells to adopt a filamentous form, followed by filtration of the sample to separate minicells from parent bacterial cells. The inventive methods optionally include one or more steps to remove endotoxin from purified minicell preparations, and/or treatment of purified minicell preparations with an antibiotic. Additionally, the invention provides purified minicell preparations, prepared according to the foregoing methods, and containing fewer than about 1 contaminating parent bacterial cell per 107, 108, 109, 1010, or 1011 minicells.
    Type: Grant
    Filed: June 24, 2003
    Date of Patent: November 3, 2009
    Assignee: Engeneic Molecular Delivery Pty, Ltd.
    Inventors: Himanshu Brahmbhatt, Jennifer MacDiarmid
  • Publication number: 20080299084
    Abstract: Intact, bacterially-derived minicells can safely introduce therapeutically effective amounts of plasmid-free functional nucleic acid to target mammalian cells. To this end, functional nucleic acid can be packaged into intact minicells directly, without resort to expression constructs, the expression machinery of the host cell, harsh chemicals or electroporation.
    Type: Application
    Filed: March 21, 2008
    Publication date: December 4, 2008
    Inventors: Himanshu Brahmbhatt, Jennifer Macdiarmid, Toby Hulf
  • Publication number: 20080188436
    Abstract: A composition comprising recombinant, intact minicells that contain a therapeutic nucleic acid molecule is disclosed. Methods for purifying a preparation of such minicells also are disclosed. Additionally, a genetic transformation method is disclosed, which comprises (i) making recombinant, intact minicells available that contain a plasmid comprised of a first nucleic acid segment, and (ii) bringing the minicells into contact with mammalian cells that are engulfing-competent, such that the minicells are engulfed by the mammalian cells, which thereafter produce an expression product of the first nucleic acid segment.
    Type: Application
    Filed: January 24, 2008
    Publication date: August 7, 2008
    Applicant: EnGeneIC Molecular Delivery Pty. Ltd.
    Inventors: Himanshu BRAHMBHATT, Jennifer Macdiarmid
  • Publication number: 20080051469
    Abstract: A composition comprising intact minicells that contain a drug molecule is useful for targeted drug delivery. One targeted drug delivery method employs bispecific ligands, comprising a first arm that carries specificity for a bacterially derived minicell surface structure and a second arm that carries specificity for a mammalian cell surface receptor, to target drug-loaded minicells to specific mammalian cells and to cause endocytosis of the minicells by the mammalian cells. Another drug delivery method exploits the natural ability of phagocytic mammalian cells to engulf minicells without the use of bispecific ligands.
    Type: Application
    Filed: January 27, 2005
    Publication date: February 28, 2008
    Applicant: EnGeneIC Gene Therapy Pty Limited
    Inventors: Himanshu Brahmbhatt, Jennifer MacDiarmid
  • Publication number: 20080038296
    Abstract: A composition comprising intact killed bacterial cells that contain a therapeutic nucleic acid, a drug or a functional nucleic acid is useful for targeted delivery to mammalian cells. The targeted delivery optionally employs bispecific ligands, comprising a first arm that carries specificity for a killed bacterial cell surface structure and a second arm that carries specificity for a mammalian cell surface receptor, to target killed bacterial cells to specific mammalian cells and to cause endocytosis of the killed bacterial cells by the mammalian cells. Alternatively, the delivery method exploits the natural ability of phagocytic mammalian cells to engulf killed bacterial cells without the use of bispecific ligands.
    Type: Application
    Filed: June 20, 2007
    Publication date: February 14, 2008
    Inventors: Himanshu Brahmbhatt, Jennifer Macdiarmid
  • Publication number: 20080020441
    Abstract: A composition comprising recombinant, intact minicells that contain a therapeutic nucleic acid molecule is disclosed. Methods for purifying a preparation of such minicells also are disclosed. Additionally, a genetic transformation method is disclosed, which comprises (i) making recombinant, intact minicells available that contain a plasmid comprised of a first nucleic acid segment, and (ii) bringing the minicells into contact with mammalian cells that are engulfing-competent, such that the minicells are engulfed by the mammalian cells, which thereafter produce an expression product of the first nucleic acid segment.
    Type: Application
    Filed: March 23, 2007
    Publication date: January 24, 2008
    Inventors: Himanshu BRAHMBHATT, Jennifer MacDiarmid
  • Publication number: 20070298056
    Abstract: Intact bacterially derived minicells containing functional nucleic acids or plasmids encoding functional nucleic acids can reduce, in targeted mammalian cells, drug resistance, apoptosis resistance, and neoplasticity, respectively. Methodology that employs minicells to deliver functional nucleic acids, targeting the transcripts of proteins that contribute to drug resistance or apoptosis resistance, inter alia, can be combined with chemotherapy to increase the effectiveness of the chemotherapy.
    Type: Application
    Filed: August 25, 2005
    Publication date: December 27, 2007
    Inventors: Himanshu Brahmbhatt, Jennifer MacDiarmid